Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161723 | 0.87 | ALDH1A1 (0.65) | ALDH1A1TSHRTHRBAPEX1EGLN1 | |
| SCHEMBL9329248 | 0.87 | ALDH1A1 (0.65) | ALDH1A1TSHRTHRBAPEX1EGLN1 | |
| SCHEMBL9500702 | 0.86 | ALDH1A1 (0.48) | ALDH1A1TSHRPTGS1THRB | |
| Methacrylic Acid SCHEMBL30076053 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRTHRBAPEX1 | |
| SCHEMBL2726802 | 0.84 | PTGS1 (0.41) | ALDH1A1PTGS1APEX1EGLN1 | |
| Methacrylic Acid SCHEMBL8375014 | 0.84 | ALDH1A1 (0.83) | ALDH1A1TSHRTHRBEGLN1ELANE | |
| Methacrylic Acid SCHEMBL10493520 | 0.84 | ALDH1A1 (0.83) | ALDH1A1TSHRTHRBEGLN1ELANE | |
| Methacrylic Acid SCHEMBL121002 | 0.84 | ALDH1A1 (0.83) | ALDH1A1TSHRTHRBEGLN1ELANE | |
| Methacrylic Acid SCHEMBL1171642 | 0.84 | ALDH1A1 (0.83) | ALDH1A1TSHRTHRBEGLN1ELANE | |
| Methacrylic Acid SCHEMBL28927748 | 0.84 | ALDH1A1 (0.83) | ALDH1A1TSHRTHRBEGLN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9205130-B2 | Orally administrable pharmaceutical pellet of epidermal growth factor | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2015-12-08 | — | — | US | claimed |
| US-20120308661-A1 | ORALLY ADMINISTRABLE PHARMACEUTICAL PELLET OF EPIDERMAL GROWTH FACTOR | BIOREC S. A. (UY) | 2012-12-06 | — | — | US | claimed |
| US-20200179288-A1 | Omeprazole Formulations | SANDOZ AG (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3380084-B1 | OMEPRAZOLE FORMULATIONS | SANDOZ AG (CH) | 2019-08-21 | — | — | EP | disclosed |
| EP-3380084-A1 | OMEPRAZOLE FORMULATIONS | Sandoz AG (CH) | 2018-10-03 | — | — | EP | disclosed |
| WO-2018046498-A1 | OMEPRAZOLE FORMULATIONS | SANDOZ AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| EP-3292862-A1 | OMEPRAZOLE FORMULATIONS | SANDOZ AG (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-2604256-B1 | Multi layer coatings | HEXAL AG (DE) | 2016-04-13 | — | — | EP | disclosed |
| US-9205130-B2 | Orally administrable pharmaceutical pellet of epidermal growth factor | CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (CU) | 2015-12-08 | — | — | US | disclosed |
| EP-2604256-A1 | Multi layer coatings | Hexal AG (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120308661-A1 | ORALLY ADMINISTRABLE PHARMACEUTICAL PELLET OF EPIDERMAL GROWTH FACTOR | BIOREC S. A. (UY) | 2012-12-06 | — | — | US | disclosed |
| US-20120082721-A1 | Enteric coating | H E X A L AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | US | disclosed |
| EP-2343054-A1 | Pellets and microparticles of pravastatin sodium and a process of making them | LEK Pharmaceuticals d.d. (SI) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011080346-A2 | PELLETS AND MICROPARTICLES OF PRAVASTATIN SODIUM AND A PROCESS OF MAKING THEM | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010136219-A1 | ENTERIC COATING | HEXAL AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| EP-2255794-A1 | Enteric coating | H e x a l Aktiengesellschaft (DE) | 2010-12-01 | — | — | EP | disclosed |